Guillen Astete Carlos, Boteanu Alina, Medina Quiñones Carmen, Garcia Montes Nuria, Roldan Moll Fernando, Carballo Carmano César, Zea Mendoza Antonio
Servicio de Reumatología, Hospital Universitario Ramón y Cajal, Madrid, España; Consulta de Urgencias Reumatológicas y Musculoesqueléticas, Servicio de Urgencias, Hospital Universitario Ramón y Cajal, Madrid, España; Servicio de Urgencias, Hospital Universitario Ramón y Cajal, Madrid, España.
Servicio de Reumatología, Hospital Universitario Ramón y Cajal, Madrid, España; Consulta de Urgencias Reumatológicas y Musculoesqueléticas, Servicio de Urgencias, Hospital Universitario Ramón y Cajal, Madrid, España; Servicio de Urgencias, Hospital Universitario Ramón y Cajal, Madrid, España.
Reumatol Clin. 2015 Jan-Feb;11(1):9-11. doi: 10.1016/j.reuma.2014.03.004. Epub 2014 Jun 2.
The purpose of this study is to determine the rate of bleeding complications in patient's anticoagulated with acenocoumarol according to the international normalized ratio (INR) coagulation index. A cross-sectional study was performed with 901 charts of patients who underwent arthrocentesis or joint infiltration between 2009 and 2013; the charts were grouped on the basis of having an INR higher or lower than 2.0 (268 and 633, respectively). Comparisons were performed in terms of rates of early or late bleeding complications. A 0.37% rate of early bleeding complications (< 24hours) was observed in the group of patients with INR<2 and 0.99% in the group of patients with INR≥2 (P=.47). Only one case of late complication was presented by bleeding between 24 hours and 30 days, in the group of patients with INR≥2. We conclude that oral anticoagulation with acenocoumarol at terapeutical doses does not increase the risk of bleeding joint punctures.
本研究的目的是根据国际标准化比值(INR)凝血指标,确定接受醋硝香豆素抗凝治疗的患者出血并发症的发生率。对2009年至2013年间接受关节穿刺或关节注射的901例患者的病历进行了横断面研究;病历根据INR高于或低于2.0进行分组(分别为268例和633例)。对早期或晚期出血并发症的发生率进行了比较。INR<2的患者组中观察到0.37%的早期出血并发症发生率(<24小时),INR≥2的患者组中为0.99%(P=0.47)。在INR≥2的患者组中,仅1例在24小时至30天之间出现晚期出血并发症。我们得出结论,治疗剂量的醋硝香豆素口服抗凝不会增加关节穿刺出血的风险。